Caveats: quarterly billing surprises people
For patients deciding between semaglutide and tirzepatide or between standard dose and microdose genetic insight can add another layer of personalization
Using a Federated Network of Real-World Data to Optimize Clinical Trials Operations
These medications, which include widely known brands, such as Wegovy and Zepbound, have reported helping patients reduce body weight and lower their risk of serious complications, including cardiovascular disease
(Exenatide is FDA approved as monotherapy for the management of T2DM.) Explicitly stated in the guideline for patients requiring dual or triple therapy, the AACE/ACE preferentially recommends the addition of a GLP-1 receptor agonist or a DPP-4 inhibitor (sitagliptin, saxagliptin), citing their efficacy and safety profiles as preferred agents over TZDs or sulfonylureas (SUs)
This makes it a valuable treatment option for those with a high risk of cardiovascular disease